Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexcom Now Offers Providers G6 Pro Continuous Glucose Monitoring Systems

Executive Summary

Dexcom announced that providers can pre-order its G6 Pro continuous glucose monitoring system starting today with shipping starting 6 July. 

You may also be interested in...



ADA 2020: Abbott Expects CGM To Reduce Insulin Needed For Type 2 Diabetes

Research presented at this year’s virtual American Diabetes Association meeting demonstrated the benefits of continuous glucose monitoring for those with type 2 diabetes not taking insulin. Mahmood Kazemi, divisional VP for global medical and scientific affairs at Abbott’s diabetes care tells Medtech Insight how he sees CGM technology transforming the future of diabetes management.

ADA 2020: CGM Maker Dexcom Gains CE Mark, Launches G6 Pro While Rivalry With Abbott Builds

Dexcom’s CEO explained the company’s strategy for continued growth, including marketing opportunities for its G6 and G6 Pro continuous glucose monitors and plans for the next-gen G7 CGM.

Medtronic Sales Slump In Q4 2020 But CEO Reveals Appetite For Tuck-In Acquisitions

Medtronic's revenue for the fourth quarter of fiscal 2020 was down 25% year-year-over due to the COVID-19 pandemic. The hardest-hit segment was restorative therapies, which reported a 33% year-over-year decline in the quarter due to the drop off in deferrable procedures and capital purchases. For the full fiscal year, Medtronic's revenue was down 4.2% to $28.9bn.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142258

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel